Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbetocin Nasal Spray for Hyperphagia in Prader-Willi Syndrome
NCT06173531Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Modality
- Peptides
- Countries
- 6
01
Overview
A Phase 3 trial of carbetocin in Prader-Willi syndrome (PWS), sponsored by Acadia Pharmaceuticals. Started Nov 2023; status: completed.
02
Drugs
carbetocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT06173531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173531.